COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Laniece Delaunay, Charlotte Verdasca, Nuno Monge, Susana Domegan, Lisa Sève, Noémie Buda, Silke Meijer, Adam Lucaccioni, Héloïse López Torrijos, Miriam McKenna, Adele
Laniece Delaunay, Charlotte
Verdasca, Nuno
Monge, Susana
Domegan, Lisa
Sève, Noémie
Buda, Silke
Meijer, Adam
Lucaccioni, Héloïse
López Torrijos, Miriam
McKenna, Adele
Series / Report no.
Open Access
Type
Journal Article
Multicenter Study
Article
Multicenter Study
Article
Language
en
Date of publication
2025-05
Year of publication
Research Projects
Organizational Units
Journal Issue
Title
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Translated Title
Published in
Influenza Other Respir 2025; 19(5):e70120
Abstract
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.